We are live on
!
Find out more
BCPEM
Bain Capital Public Equity Management Portfolio holdings
AUM
$1.05B
1-Year Est. Return
25.71%
This Fund
S&P 500
This Quarter
Est. Return
+11.26%
1 Year Est. Return
+25.71%
3 Year Est. Return
+127.65%
5 Year Est. Return
+213.44%
10 Year Est. Return
–
AUM
$1.48B
AUM Growth
+$108M
(+7.9%)
Cap. Flow
+$50.4M
Cap. Flow
% of AUM
3.4%
Top 10 Holdings %
Top 10 Hldgs %
59.27%
Holding
99
New
32
Increased
13
Reduced
17
Closed
36
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
DOCU
DocuSign
DOCU
|
+$328M |
| 2 |
SLB Ltd
SLB
|
+$46.5M |
| 3 |
Alphabet (Google) Class A
GOOGL
|
+$45.5M |
| 4 |
Meta Platforms (Facebook)
META
|
+$39.8M |
| 5 |
Novartis
NVS
|
+$39.5M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
AABA
Altaba Inc
AABA
|
+$290M |
| 2 |
MULE
MuleSoft, Inc.
MULE
|
+$67.2M |
| 3 |
NXP Semiconductors
NXPI
|
+$28.3M |
| 4 |
Boeing
BA
|
+$22.6M |
| 5 |
AstraZeneca
AZN
|
+$22.4M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 43.27% |
| 2 | Consumer Discretionary | 12.69% |
| 3 | Healthcare | 12.46% |
| 4 | Industrials | 11.24% |
| 5 | Communication Services | 9.47% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
ARRY
51
DELISTED
Array Biopharma Inc
ARRY
| $2.2M | 0.15% |
130,844
-22,582
| -15% | -$359K |
|
|
SGMO
52
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
| $2M | 0.14% |
+140,992
| New | +$2.34M |
|
|
MDCO
53
DELISTED
Medicines Co
MDCO
| $1.94M | 0.13% |
52,807
-3,697
| -7% | -$120K |
|
54
CALL
Ball Corp
BALL
$16.1B
| $1.19M | 0.08% |
7,000
+4,500
| +180% | +$172K |
|
55
PUT
iShares Russell 1000 Growth ETF
IWF
$123B
| $1.1M | 0.07% |
+15,360
| New | +$542K |
|
56
PUT
GE Aerospace
GE
$319B
| $850K | 0.06% |
+17,736
| New | +$1.18M |
|
57
PUT
AbbVie
ABBV
$465B
| $581K | 0.04% |
+1,400
| New | +$137K |
|
|
GBT
58
CALL
DELISTED
Global Blood Therapeutics, Inc.
GBT
| $524K | 0.04% |
+435
| New | +$19.8K |
|
59
CALL
BioMarin Pharmaceuticals
BMRN
$12.5B
| $500K | 0.03% |
+1,086
| New | +$95.1K |
|
60
PUT
State Street SPDR S&P Biotech ETF
XBI
$10.4B
| $462K | 0.03% |
+1,400
| New | +$129K |
|
|
61
CALL
Novartis
NVS
$263B
| $252K | 0.02% |
+1,703
| New | +$118K |
|
62
Curis
CRIS
$2.74M
| $170K | 0.01% |
246
-42
| -15% | -$43K |
|
|
NTGN
63
DELISTED
Neon Therapeutics, Inc. Common Stock
NTGN
| $147K | 0.01% |
+11,706
| New | +$160K |
|
64
PUT
Amgen
AMGN
$203B
| – | – |
-865
| Closed | -$917K |
|
|
65
CALL
AstraZeneca
AZN
$251B
| – | – |
-1,800
| Closed | -$480K |
|
|
66
AstraZeneca
AZN
$251B
| – | – |
-320,936
| Closed | -$22.4M |
|
|
67
Boeing
BA
$166B
| – | – |
-68,831
| Closed | -$22.6M |
|
68
CALL
Bristol-Myers Squibb
BMY
$130B
| – | – |
-1,750
| Closed | -$168K |
|
|
69
PUT
Bristol-Myers Squibb
BMY
$130B
| – | – |
-1,500
| Closed | -$241K |
|
70
Comcast
CMCSA
$86.7B
| – | – |
-467,557
| Closed | -$16M |
|
71
Essent Group
ESNT
$6.13B
| – | – |
-281,039
| Closed | -$12M |
|
72
Eaton
ETN
$152B
| – | – |
-164,765
| Closed | -$13.2M |
|
73
CALL
Exelixis
EXEL
$14.1B
| – | – |
-2,850
| Closed | -$135K |
|
|
74
Exelixis
EXEL
$14.1B
| – | – |
-74,802
| Closed | -$1.66M |
|
|
GES
75
DELISTED
Guess Inc
GES
| – | – |
-371,545
| Closed | -$7.71M |
|
Similar funds
WF
DCM
AB
MFBTD
IAS
SA
TL
ACM
Bain Capital Public Equity Management's Q2 2018 Portfolio in Review
As of Q2 2018, Bain Capital Public Equity Management held 99 positions worth $1.48B, up 7.9% from $1.37B the previous quarter. Its ten largest holdings account for 59% of the portfolio.
Bain Capital Public Equity Management deployed $50.4M of net new capital in Q2 2018, opening 32 new positions and adding to 13 existing holdings. Its largest new stake was DocuSign: 6,491,125 shares worth $344M.
By sector, the portfolio is most concentrated in Technology at 43% of assets, down from 47% a quarter earlier, followed by Consumer Discretionary and Healthcare.
On the sell side, the largest reduction was Altaba Inc, an estimated $290M trimmed.
- Bain Capital Public Equity Management's largest Q2 2018 buy was DocuSign: 6,491,125 shares worth $344M.
- Bain Capital Public Equity Management added most to Vertex Pharmaceuticals in Q2 2018, an estimated $23.4M increase.
- Bain Capital Public Equity Management's biggest Q2 2018 reduction was Altaba Inc, cutting an estimated $290M.
- Bain Capital Public Equity Management fully exited MuleSoft, Inc. in Q2 2018, selling an estimated $67.2M.
- Bain Capital Public Equity Management's ten largest holdings make up 59% of its $1.48B portfolio in Q2 2018.
- Bain Capital Public Equity Management opened 32 new positions and closed 36 in Q2 2018.
- Bain Capital Public Equity Management's portfolio value rose 7.9% quarter-over-quarter to $1.48B.
Based on Bain Capital Public Equity Management's 13F filing for Q2 2018, filed 14 Aug 2018.